Naibec supplies substances to US-based multinational pharmaceutical company... "Developing new drug substances for chronic diseases such as pulmonary fibrosis"

[Asia Economy Reporter Hyunseok Yoo] Naivek announced on the 18th that it will officially begin supplying protein therapeutic drug candidate substances to a US-based multinational pharmaceutical company. This supply is based on a joint research and material supply agreement signed with the US-based multinational pharmaceutical company, targeting the preclinical stage, with indications including pulmonary fibrosis and other lung diseases, as well as chronic diseases such as heart failure.

Naivek had already signed a supply contract with the US-based multinational pharmaceutical company in January of last year. Through joint research with the pharmaceutical company, Naivek succeeded in developing a protein drug candidate substance with optimized functions, and based on this, it began full-scale supply of new drug development candidate substances starting this month.

The development of candidate substances requested by the multinational pharmaceutical company began rapidly in the second half of last year. Naivek has already secured GMP production cell lines and started producing high-purity proteins, making it possible to supply materials in earnest from this month. Since no pharmaceutical company has secured cell lines with commercialization of proteins in mind until now, if the new drug development is completed, Naivek will be able to take charge of contract manufacturing of the drug as well.

A Naivek official said, “The new drug pipeline being developed by the global pharmaceutical company is a candidate substance for treating chronic diseases including cardiopulmonary diseases such as pulmonary fibrosis, and since it corresponds to the preclinical stage of clinical development, the required quantity is considerable,” adding, “Because the development period is quite long, a large amount of therapeutic proteins supplied by Naivek will be needed over an extended period depending on the progress of candidate substance research.”

He continued, “We received feedback that the pharmaceutical company was satisfied with Naivek’s expertise and quality regarding the protein therapeutics supplied,” and added, “Sales are expected to increase significantly as the supply volume grows in the future.”

The official emphasized, “Chronic disease treatments including pulmonary fibrosis and cardiopulmonary diseases are being researched by global pharmaceutical companies focusing on various mechanisms, but products have mainly been developed based on small molecule compounds that have severe side effects with long-term use. However, these are also facing patent expirations, so there is an urgent need for new mechanism drugs, and global pharmaceutical companies have high interest in the supply materials exclusively held by Naivek.”

Naivek is considering expanding its protein drug raw material production facilities to prepare for an increase in supply volume in the future. The company explained that, following upgraded material development, the supply of protein therapeutic drug substances, which are considered highly challenging, has proceeded smoothly, so there is a high possibility that joint development projects involving global pharmaceutical companies from the preclinical stage of new drug development will increase.

This content was produced with the assistance of AI translation services.